Korea's Daewoong Pharmaceutical has extended its botulinum toxin Nabota to 10 of the 20 countries in the Middle East and North Africa after signing export contracts with Iraq and Bahrain, the company said Monday.
The expansion follows launches this year in Saudi Arabia and Qatar and builds on earlier entries since 2020 in the UAE, Turkey and Egypt. Daewoong said it is treating the Middle East as a strategic hub after establishing Nabota in North America, Europe and Latin America.
The company aims to pitch Nabota as a premium toxin through physician training and academic support to boost procedure quality. Daewoong plans to host its first region-specific Nabota Master Class, NMC MENA, in Saudi Arabia later this year, with about 100 physicians expected.
Demand signals remain strong: more than half of the region’s population is under 30, and aesthetics trends are spreading via social media, according to Daewoong.
Related articles
- Daewoong signs $24.5 mil. Nabota export deal with Colombia’s Valentech Pharma
- Daewoong pulls BTX filing in China to align with regulatory changes
- Daewoong expands Middle East presence with Nabota launch in Kuwait
- Daewoong launches K-aesthetic treatments in Indonesia, led by Botox rival Nabota
- Korea urged to drop botulinum toxin from ‘core national technologies’ amid global market loss
- Daewoong confirms safety and continued progress of P2 trial for IPF drug
- Daewoong Pharm expands Nabota Master Class to train global doctors, strengthen K-beauty leadership
- Daewoong showcases microneedle, biosimilar tech at CPHI Worldwide 2025
- Daewoong hosts Nabota BTX master class to strengthen brand in Argentina